Appendix 3B
Released
Released
Announcement PDF
Appendix 3B
Rule 2.7, 3.10.3, 3.10.4, 3.10.5
New issue announcement,
application for quotation of additional securities
and agreement
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12
Name of entity
Mayne Pharma Group Limited (Company)
ABN
76 115 832 963
We (the entity) give ASX the following information.
Part 1 - All issues
You must complete the relevant sections (attach sheets if there is not enough space).
1
+Class of +securities issued or to
be issued
Fully paid ordinary shares in the Company
2
Number of +securities issued or to
be issued (if known) or maximum
number which may be issued
1,000,000 ordinary shares
3
Principal terms of the +securities
(eg, if options, exercise price and
expiry date; if partly paid
+securities, the amount outstanding
and due dates for payment; if
+convertible
securities,
the
conversion price and dates for
conversion)
Fully paid ordinary shares
4
Do the +securities rank equally in
all respects from the date of
allotment with an existing +class of
quoted +securities?
Yes.
If the additional securities do not
rank equally, please state:
the date from which they do
the extent to which they
participate for the next
dividend, (in the case of a trust,
distribution)
or
interest
payment
the extent to which they do not
rank equally, other than in
relation to the next dividend,
distribution or interest payment
5
Issue price or consideration
$0.2327 per share
6
Purpose of the issue
(If issued as consideration for the
acquisition of assets, clearly
identify those assets)
Exercise of unlisted options for ordinary shares
6a
Is the entity an +eligible entity that
has obtained security holder
approval under rule 7.1A?
Not applicable.
If Yes, complete sections 6b – 6h
in relation to the +securities the
subject of this Appendix 3B, and
comply with section 6i
6b
The date the security holder
resolution under rule 7.1A was
passed
Not applicable.
6c
Number of +securities issued
without security holder approval
under rule 7.1
Not applicable.
6d
Number of +securities issued with
security holder approval under rule
7.1A
Number of +securities issued with
security holder approval under rule
7.3, or another specific security
holder approval (specify date of
meeting)
Not applicable.
Number of securities issued under
an exception in rule 7.2
Not applicable.
6e
6f
Not applicable.
+ See chapter 19 for defined terms.
Appendix 3B Page 2
10/02/2015
6g
If securities issued under rule
7.1A, was issue price at least 75%
of 15 day VWAP as calculated
under rule 7.1A.3? Include the
issue date and both values. Include
the source of the VWAP
calculation.
Not applicable.
6h
If securities were issued under rule
7.1A for non-cash consideration,
state date on which valuation of
consideration was released to ASX
Market Announcements
Not applicable.
6i
Calculate the entity’s remaining
issue capacity under rule 7.1 and
rule 7.1A – complete Annexure 1
and release to ASX Market
Announcements
Not applicable.
7
Dates of entering +securities into
uncertificated holdings or despatch
of certificates
19 January 2016
8
9
Number and +class of all
+securities
quoted on ASX
(including the securities in section
2 if applicable)
+class
Number and
of all
+securities not quoted on ASX
(including the securities in section
2 if applicable)
Number
808,196,346
Number
7,500,000
26,360,000
10
Dividend policy (in the case of a
trust, distribution policy) on the
increased capital (interests)
Not applicable.
+Class
Fully paid ordinary shares.
+Class
Employee options pursuant to
CEO Share Option Plan.
Expiring 13 February 2019
exercisable at $0.2435 each.
Employee options pursuant to
Mayne Pharma Employee Share
Option Plan. (Refer Appendix 1
for further detail)
Part 2 - Bonus issue or pro rata issue
11
Is
security
required?
holder
approval
Not applicable.
12
Is the issue renounceable or nonrenounceable?
Not applicable.
13
Ratio in which the +securities will
be offered
Not applicable.
14
+Class
of +securities to which the
offer relates
Not applicable.
15
+Record
determine
Not applicable.
16
Will holdings on different registers
(or subregisters) be aggregated for
calculating entitlements?
Not applicable.
17
Policy for deciding entitlements in
relation to fractions
Not applicable.
18
Names of countries in which the
entity has +security holders who
will not be sent new issue
documents
Not applicable.
date
to
entitlements
Note: Security holders must be told how their
entitlements are to be dealt with.
Cross reference: rule 7.7.
19
Closing date for receipt
acceptances or renunciations
of
Not applicable.
20
Names of any underwriters
Not applicable.
21
Amount of any underwriting fee or
commission
Not applicable.
22
Names of any brokers to the issue
Not applicable.
23
Fee or commission payable to the
broker to the issue
Not applicable.
24
Amount of any handling fee payable
to brokers who lodge acceptances
or renunciations on behalf of
+security holders
Not applicable.
+ See chapter 19 for defined terms.
Appendix 3B Page 4
10/02/2015
25
If the issue is contingent on
+security holders’ approval, the date
of the meeting
Not applicable.
26
Date entitlement and acceptance
form and prospectus or Product
Disclosure Statement will be sent to
persons entitled
Not applicable.
27
If the entity has issued options, and
the terms entitle option holders to
participate on exercise, the date on
which notices will be sent to option
holders
Not applicable.
28
Date rights trading will begin (if
applicable)
Not applicable.
29
Date rights trading will end (if
applicable)
Not applicable.
30
How do +security holders sell their
entitlements in full through a
broker?
Not applicable.
31
How do +security holders sell part
of their entitlements through a
broker and accept for the balance?
Not applicable.
32
How do +security holders dispose of
their entitlements (except by sale
through a broker)?
Not applicable.
33
+Despatch date
Not applicable.
Part 3 - Quotation of securities
You need only complete this section if you are applying for quotation of securities
34
Type of securities
(tick one)
(a)
Securities described in Part 1
(b)
All other securities
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee
incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entities that have ticked box 34(a)
Additional securities forming a new class of securities
Tick to indicate you are providing the information or
documents
35
If the securities are equity securities, the names of the 20 largest holders of the
additional securities, and the number and percentage of additional securities held by
+
+
+
+
those holders
36
If the securities are equity securities, a distribution schedule of the additional
securities setting out the number of holders in the categories
+
+
+
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over
37
+
A copy of any trust deed for the additional securities
+ See chapter 19 for defined terms.
Appendix 3B Page 6
10/02/2015
Entities that have ticked box 34(b)
38
Number of securities for which
+quotation is sought
39
Class of +securities
quotation is sought
40
Do the +securities rank equally in all
respects from the date of allotment
with an existing +class of quoted
+securities?
for
which
If the additional securities do not
rank equally, please state:
the date from which they do
the extent to which they
participate for the next dividend,
(in the case of a trust,
distribution) or interest payment
the extent to which they do not
rank equally, other than in
relation to the next dividend,
distribution or interest payment
41
Reason for request for quotation
now
Example: In the case of restricted securities, end of
restriction period
(if issued upon conversion of
another security, clearly identify that
other security)
Number
42
Number and +class of all +securities
quoted on ASX (including the
securities in clause 38)
+Class
Quotation agreement
1
+Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote
the +securities on any conditions it decides.
2
We warrant the following to ASX.
The issue of the +securities to be quoted complies with the law and is not for an
illegal purpose.
There is no reason why those +securities should not be granted +quotation.
An offer of the +securities for sale within 12 months after their issue will not require
disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
Note: An entity may need to obtain appropriate warranties from subscribers for the
securities in order to be able to give this warranty
Section 724 or section 1016E of the Corporations Act does not apply to any
applications received by us in relation to any +securities to be quoted and that noone has any right to return any +securities to be quoted under sections 737, 738 or
1016F of the Corporations Act at the time that we request that the +securities be
quoted.
If we are a trust, we warrant that no person has the right to return the +securities to
be quoted under section 1019B of the Corporations Act at the time that we request
that the +securities be quoted.
3
We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action
or expense arising from or connected with any breach of the warranties in this agreement.
4
We give ASX the information and documents required by this form. If any information or
document not available now, will give it to ASX before +quotation of the +securities begins.
We acknowledge that ASX is relying on the information and documents. We warrant that
they are (will be) true and complete.
Sign here:
............................................................
(Company secretary)
Print name:
Mark Cansdale
Date: 19 January 2016
+ See chapter 19 for defined terms.
Appendix 3B Page 8
10/02/2015
MAYNE PHARMA GROUP LIMITED
APPENDIX 1 – EMPLOYEE OPTIONS ISSUED UNDER
EMPLOYEE SHARE OPTION PLAN
Employee options
Expiry date
Exercise Price
Vested
Unvested Total number of shares
issued under option
12/01/2019
$
0.3127
1,820,000
7,400,000
9,220,000
26/01/2019
$
0.3127
160,000
6,080,000
6,240,000
7/03/2019
$
0.3927
800,000
800,000
28/03/2019
$
0.8946
600,000
600,000
19/06/2019
$
0.8644
120,000
480,000
600,000
30/06/2019
$
0.9131
200,000
800,000
1,000,000
1/07/2019
$
0.4127
200,000
800,000
1,000,000
2/07/2019
$
0.9052
80,000
320,000
400,000
1/08/2019
$
0.8380
200,000
200,000
28/08/2019
$
0.8625
120,000
480,000
600,000
21/10/2019
$
0.6866
80,000
320,000
400,000
11/11/2019
$
0.7590
200,000
800,000
1,000,000
30/11/2019
$
0.7697
200,000
800,000
1,000,000
17/12/2019
$
0.7390
120,000
480,000
600,000
1/02/2020
$
0.6290
540,000
2,160,000
2,700,000
3,840,000
22,520,000
26,360,000
Total
+ See chapter 19 for defined terms.
01/08/2012
Appendix 3B Page 9
Share your feedback
Discover